COVID-19 Information

Funding

Current Research Support:

R01 CA200994 (PI: Miller) 04/01/2017 – 03/31/2022
NIH/NCI
Project: A precision medicine basis for estrogen therapy for advanced breast cancer.
Role: PI

R01 CA211869 (PI: Miller) 09/04/2017 – 08/31/2022
NIH/NCI/NIGMS
Project: A precision medicine basis for Pl3K inhibition in ER+ breast cancer.
Role: PI

Career Catalyst Research Grant (PI: Miller) 07/01/2015– 06/30/2018
Susan G. Komen
Project: Estrogen receptor reactivation for treatment of advanced breast cancer
Role: PI

Pilot Project Grant (PI: Miller) 08/01/2014 – open
Norris Cotton Cancer Center Early-Phase Trials Program (no salary)
Project: Alternating estradiol and anti-estrogen therapies to prevent disease progression in advanced ER+/HER2- breast cancer.
Role: PI

Investigator-initiated Phase I clinical study (PI: Schwartz) 10/01/2015 – 04/30/2017
Takeda Pharmaceuticals
Project: Phase 1 study of combination of MLN9708 and Fulvestrant in patients with advanced ER+ breast cancer.
Role: Co-Investigator

Pilot Project Grant (Co-PIs: Kettenbach, Miller) 10/01/2015 - 09/30/2016
Prouty / Norris Cotton Cancer Center
Project: Development of a “BRCA-like” protein signature for identification of triple-negative breast cancers with homologous recombination DNA repair deficiency
Role: Co-PI

Investigator-initiated Phase I clinical study (PI: Fadul, Univ. of Virginia) 04/01/2016 – 10/01/2017
Novartis Pharmaceuticals
Project: Early-phase study to assess tumor pharmacokinetics and efficacy of the CDK4/6 inhibitor ribociclib (LEE011) in patients with recurrent glioblastoma or anaplastic glioma.
Role: Co-Investigator

Program Project Grant Seed Funding (PI: Miller) 11/01/2015 – 10/31/2017
Norris Cotton Cancer Center
Program: Development and management of early-stage breast cancer.
Role: Program Initiator, Co-Leader, and Project #4 PI

Pilot Project Grant (Co-PIs: Diamond, Miller) 10/01/2016 – 09/30/2018
Prouty / Norris Cotton Cancer Center
Project: An image-guided drug delivery platform for precision medicine in cancer
Role: Co-PI

Pilot Project Grant (Co-PIs: Mierke, Miller) 01/01/2017 – 12/31/2018
Prouty / Norris Cotton Cancer Center
Project: Identification of novel inhibitors of Rac1
Role: Co-PI

Investigator-initiated Phase I clinical study (PI: Schwartz) 04/01/2017 – 11/30/2018
Takeda Pharmaceuticals
Project: Phase 1b neoadjuvant run-in study with TAK-228 followed by Letrozole/TAK-228 in women with high-risk ER+/HER2- breast cancer.
Role: Co-Investigator

Completed Research Support:

Research Grant (PI: Miller) 07/01/2015 – 06/30/2017
The Mary Kay Foundation
Project: Mechanisms underlying dormancy in ER+ breast cancer
Role: PI

RSG-13-292-01-TBE (PI: Miller) 07/01/2013 – 06/30/2017
American Cancer Society
Project: Targeting PI3K and ER pathways in antiestrogen-resistant breast cancer
Role: PI

K99 CA142899 (PI: Miller) 09/03/2010 – 07/31/2015
R00 CA142899
NIH/NCI
Project: The effects of PTEN on tyrosine kinase signaling in breast cancer .
Role: PI

Research Grant (Co-PIs: Ronan, Miller) 07/01/2014 – 12/31/2016
The Hitchcock Foundation
Project: Pilot study to develop circulating tumor DNA in cerebrospinal fluid as an early biomarker of leptomeningeal carcinomatosis in patients with metastatic solid tumor cancer.
Role: Co-PI

Clinical Research Pilot Grant (Co-PIs: Miller, Chamberlin) 01/01/2013 – 07/31/2015
The Hopeman Foundation / Norris Cotton Cancer Center
Project: Plasma DNA as a surrogate for tumor biopsy to identify tumor genetic alterations in patients with advanced breast cancer.
Role: Co-PI

Management of Cancer Grant (PI: Miller) 11/17/2012 – 07/31/2015
Doctors’ Cancer Foundation
Project: Circulating tumor DNA as a biomarker of disease burden and response to cytotoxic therapy.
Role: PI

Research Grant (PI: Miller) 08/01/2012 – 05/01/2014
Piramal Life Sciences, Ltd.
Project: Abrogating endocrine resistance in ER+ breast cancer using P1446, P7170, and PL225B.
Role: PI